Skip to content
中文EN

Cardiometabolic

GLP-1 and obesity, Lp(a), heart failure and arrhythmia — pivotal trials and industry shape.

260 picksRelatedClinical readoutsDeals & financingNucleic acid drugs

Latest picks

21–39 of 260
Oct 16Fri
  1. BioPharma Dive65

    Next-gen RNAi drugmaker City prices $200M IPO

    City Therapeutics raised $200 million in its IPO, selling just over 11.1 million shares at $18 each, and begins Nasdaq trading Friday under ticker CTY. Co-founded by former Alnylam CEO John Maraganore, the company develops RNA interference therapies, with lead candidate CITY-FXI targeting Factor XI for thromboembolic diseases and a first Phase 2 trial in knee-replacement patients expected next year. Its CITY-RBP4 program for Stargardt disease enters Phase 1 later this year, and an anemia of chronic disease program starts an early-stage study in 2027.

    Why it matters: IPO pricing by an RNAi startup led by a well-known biotech founder, with pipeline milestones scheduled through 2027.

  2. Nature54

    Real-world, digital-first delivery of GLP-1 receptor agonist therapy in women

    A structured clinical-digital hybrid program delivered GLP-1 receptor agonist therapy to 8,127 women from a community-based population over 6 months, with monthly clinician-led review, supervised weight confirmation and structured side effect mitigation. Of 16,121 individuals meeting initial screening criteria, 4,025 were excluded for not completing baseline blood testing and 308 after clinical review. Mean baseline weight was 104.2 kg and mean BMI 38.2 kg per m2, with 95.5% meeting criteria for class I to III obesity. It is one of the largest real-world evaluations of GLP-1RA therapy in a female community cohort and complements trial findings that enrolled predominantly male populations.

    Why it matters: It provides large real-world evidence on GLP-1RA delivery to women, a majority user group underrepresented in cardiometabolic outcomes trials.

  3. Medical Xpress63

    How heart failure reshapes bone marrow to create inflammation-related immune memory

    A team including Science Tokyo found that heart failure reduces HBEGF-producing mesenchymal stromal cells in bone marrow, shaping inflammatory immune memory and worsening cardiac dysfunction. Heart failure suppressed Notch–HES1 signaling in Lepr⁺ MSCs, driving their conversion into adipocytes; with HBEGF down, hematopoietic stem cells shifted toward myeloid cells and CCR2-high macrophages increased. Transplanting MSCs from HF mice reproduced cardiac remodeling, and human bone marrow data showed about a tenfold increase in fat.

    Why it matters: Links HBEGF loss in bone marrow MSCs to inflammatory immune memory in heart failure, offering a mechanistic entry point for target exploration.

Oct 15Thu
  1. Nature76

    Artificial intelligence-enabled clinical phenotyping of human brown fat.

    A research team used AI to systematically analyze brown adipose tissue (BAT) in 101,243 patients from a cancer center, finding that BAT was associated with lower prevalence of cardiovascular and psychiatric diseases. Using machine learning, they semi-automatically quantified BAT activity in approximately 8,700 patients and found that higher activity, especially in the axillary depot, was linked to healthier metabolism, with better blood glucose, lipid, inflammatory and echocardiographic measures.

    Why it matters: The brief gives a 100,000-patient cohort, AI-based quantification in about 8,700 patients, and losartan as a repurposing candidate for BAT activation.

  2. WeChat73

    NMPA Approves New Nuohejie Indication for Oral-Therapy-Failed Type 2 Diabetes, a World First

    Novo Nordisk's Nuohejie (insulin icodec and semaglutide injection, the first and only weekly basal insulin/GLP-1 receptor agonist) has received NMPA approval on October 15, 2026 for an added indication covering adults with type 2 diabetes whose blood glucose is inadequately controlled on oral antidiabetic drugs. China is the first country to approve this indication for the product.

    Why it matters: Regulatory approval broadens the treated population for a first-in-class weekly combination therapy in China.

  4. WeChat68

    Zealand Pharma Pays $1.2 Billion for Generate Biomedicines AI-Designed Multispecific Proteins to Extend Obesity Pipeline

    Zealand Pharma is paying $1.2 billion to bring Generate Biomedicines' AI-designed multispecific proteins into its obesity pipeline, adding a new modality alongside petrelintide, a long-acting amylin analogue, and survodutide, a glucagon/GLP-1 dual receptor agonist, both in Phase III. The Danish biotech's move comes after recent Phase III data for both candidates fell short of analyst expectations, putting pressure on its shares.

    Why it matters: A $1.2 billion licensing deal adds an AI-designed protein modality to a prominent obesity pipeline after weak Phase III results.

  5. WeChat71

    Roche licenses Rona Therapeutics' ALK7 RNAi candidate for obesity in deal worth up to $1.16 billion

    Rona Therapeutics granted Roche an exclusive global license on October 13, 2026 to an RNAi candidate targeting ALK7 (ACVR1C), developed on its APOLLO extra-hepatic delivery platform, for the treatment of obesity and metabolic diseases. The deal carries potential total payments of up to $1.16 billion plus tiered royalties on global sales. Roche takes on worldwide development and commercialization rights.

    Why it matters: Large biotech-pharma licensing deal for a differentiated obesity-targeting RNAi asset.

  6. Nature71

    Artificial intelligence-enabled clinical phenotyping of human brown fat

    AI-enabled quantification of brown adipose tissue (BAT) activity in humans links higher BAT activity to a healthier metabolic profile and lower rates of psychiatric disease. The same approach identified existing pharmacologic agents that could be repurposed to activate BAT in humans. The work provides a scalable way to phenotype BAT and connect it to clinical outcomes and drug targets.

    Why it matters: It shows AI-based BAT phenotyping at scale, linking brown fat to metabolic and psychiatric outcomes and to repurposable drugs.

  7. Nature81

    Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades

    Myosin inhibition produces vasodilation that is selective for capillaries and halts the cascades that follow ischaemia, as reported in this work on microvascular obstruction. The approach targets the capillary level, where pericyte-mediated constriction has been linked to no-reflow after ischaemia in the brain, heart and kidney. No quantitative outcome data are reported here.

    Why it matters: It addresses capillary-level no-reflow, a mechanism implicated in stroke, myocardial infarction and kidney injury.

  8. YouTube72

    Michael Hall Explains How TOR Controls Cell Growth, From Yeast Rapamycin Mutants to Human Disease

    Michael Hall explains that TOR, a highly conserved protein kinase first identified in 1991 through yeast mutants resistant to rapamycin, controls cell growth by size and mass rather than cell-cycle G1 progression. Rapamycin exerts toxicity as a complex with FKBP12 binding specific sites on TOR. TORC1 and TORC2 are conserved from yeast to humans, and TOR dysregulation links to cancer, cardiac hypertrophy, obesity and type 2 diabetes, with metformin partly acting through TOR inhibition.

    Why it matters: Clarifies the foundational TOR growth-control mechanism that underpins rapamycin and metformin biology relevant to disease research.

Oct 14Wed
  1. VBData86

    Samsung Biologics' $1.8 Billion PolyPeptide Takeover Clears Acceptance Hurdle

    Samsung Biologics' all-cash tender offer for the Swiss peptide CDMO PolyPeptide Group AG at CHF 44.31 per share, valuing it at about CHF 1.46 billion (roughly $1.8 billion), cleared its key hurdle when 87.59% of shares were tendered by the October 12 deadline. The deal, the largest ever in Korea's pharma and biotech industry, extends Samsung Biologics into peptides including GLP-1 services, backed by PolyPeptide's six GMP plants. Definitive interim results come October 16, with an additional acceptance period through October 30 and completion expected by end of 2026, followed by a squeeze-out and delisting from the Swiss exchange.

    Why it matters: Largest pharma M&A deal in Korean history extends Samsung Biologics into the fast-growing GLP-1 peptide CDMO market.

  2. Medical Xpress88

    Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds

    In the Phase III TRIUMPH-2 trial, Eli Lilly's triple agonist retatrutide produced average weight losses of 11.9%, 16.8% and 18.8% after 80 weeks of once-weekly 4/9/12 mg dosing in 1,152 patients with obesity and type 2 diabetes, versus 5.1% with placebo. In the 12 mg group, 75% of participants lost at least 10% and nearly one-third lost at least 25%.

    Why it matters: Gives three-dose weight loss and HbA1c improvements for direct comparison with semaglutide and tirzepatide in the same indication.

  4. BioPharma Dive56

    Another Paragon spinout goes public through reverse merger

    Alaunos Therapeutics acquired Velaris Therapeutics, Paragon Labs' ninth spinout, in a reverse merger that takes the cardiopulmonary disease drug developer public. Fairmount Funds, which founded Paragon in 2021, led a concurrent private placement of about $350 million, with investors including Venrock, Wellington Management and T. Rowe Price accounts, funding operations into 2029. Four of the combined company's five board directors will come from or be picked by Fairmount, and the business will advance Velaris' programs plus an obesity and metabolic disorder drug from Alaunos.

    Why it matters: Reverse mergers have surged to more than two dozen announced this year, matching IPO counts, and Velaris extends the Paragon-Fairmount model.

  5. WeChat71

    Roche Pays $100 Million Upfront for Rona Bio ALK7 Obesity Programme Rights

    Roche has licensed rights to Rona Bio's ALK7 obesity programme, with deal terms reaching up to $1.16 billion in total. Rona Bio receives $100 million upfront and is eligible for up to $1.06 billion in additional payments tied to development, regulatory and commercialisation milestones. The article does not state further trial or next-step details.

    Why it matters: A large pharma licence deal for an obesity target with disclosed upfront and milestone payments.

Oct 13Tue
  1. JAMA68

    Development and Validation of an Adult Medical Urgency Score for US Donor Heart Allocation.

    A continuous medical urgency score for US donor heart allocation, the US Candidate Risk Score (US-CRS), built from 5 laboratory values and 4 therapeutic devices, outperformed the current 6-status system for predicting 6-week waitlist mortality (test-set mean time-dependent AUC 0.807 vs 0.693). In a match-run simulation of 45,530 donor hearts, US-CRS-based allocation moved 67% of transplant recipients down in rank order and raised 6-week transplant-censored mortality for the first-listed candidate from 11.2% to 15.7%, indicating the sickest candidates are prioritized earlier.

    Why it matters: It offers a validated, objective alternative to the current 6-status US donor heart allocation system.

Oct 12Mon
  1. 顶刊论文（社媒热度）57

    ALIX-dependent small extracellular vesicles from tissue-resident mesenchymal cells regulate pancreatic β cell proliferation in obesity.

    Deleting ALIX in PDGFRα+ mesenchymal progenitors of mice blocks small extracellular vesicle production and disrupts metabolism. In high-fat diet-induced obesity, these knockout mice gained less weight and had smaller subcutaneous adipocytes, yet showed impaired glucose tolerance with reduced pancreatic β cell area and smaller islets despite normal insulin sensitivity. Conditioned-media sEVs from knockout mesenchymal stem cells lost the ability to promote β cell proliferation, identifying mesenchymal sEVs as regulators of β cell proliferation in obesity.

    Why it matters: Identifies mesenchymal-cell-derived vesicles as a required signal for pancreatic β cell proliferation in obesity.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org